TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01018849

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: cholecalciferol 150,000 IU by mouth every 2 months for 1 year
Study: NCT02591173

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Normal saline will be used as the placebo comparator.
Study: NCT00571909

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: video thorascopic splanchnicectomy (VSPL)
Description: VSPL is a minimally invasive technique using 1-2cm incisions through which a camera and surgical tools are placed inside the thoracic cavity and the idea of the procedure is to cut the pain pathway linking the splanchnic ganglion with pain centers in the hypothalamus
Study: NCT03975673

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hip replacement
Description: Osteoarthritic patient undergoing the conventional technique or the kinematically aligned technique
Study: NCT00566969

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: Subjects randomized to placebo, carvedilol 25mg or 50mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol 25 mg
Description: subjects randomized to placebo, carvedilol 25mg or 50mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol 50 mg
Description: subjects randomized to placebo, carvedilol 25mg or 50mg
Study: NCT01304017

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: The VR-therapy will include the playing of various virtual reality or video-games which encourages the use of the extremities while sitting and standing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Therapy
Description: The traditional therapy will include exercise for balance and walking and for the upper extremity using traditional therapeutic tools such as balls, weights, chairs, bands, steps, etc.
Study: NCT01684306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: Study subjects received, in a double blind fashion, either a single dose (100 mg) of modafinil or a placebo pill identical to the drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Study subjects received, in a double blind fashion, either a single dose (100 mg) of modafinil or a placebo pill identical to the drug.
Study: NCT01018849

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo by mouth every 2 months for 1 year
Study: NCT06364566

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemradiotherapy
Description: Patients receiving neoadjuvant chemradiotherapy cause tumor shrinkage

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemradiotherapy
Description: Patients receiving neoadjuvant chemradiotherapy cause tumor shrinkage

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive esophagectomy
Description: The patient underwent minimally invasive esophagectomy to remove residual tumors and surrounding lymph nodes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive esophagectomy
Description: The patient underwent minimally invasive esophagectomy to remove residual tumors and surrounding lymph nodes
Study: NCT02341794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin (5mg) will be orally administrated once daily. Dose of rosuvastatin will be adjusted to control serum LDL-c level under 1.8 mmol/L.
Study: NCT02969473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Radiotherapy: All patients underwent conventional radiotherapy, 1.8-2.0 Gy per fraction and 5 fractions per week. The prescribed dose was 60-64 Gy to PTV1 and 50 Gy to PTV2. Patients received either three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiation therapy (IMRT). 3D-CRT treatment plans were calculated by Pinnacle planning system and IMRT treatment plans were calculated by Monacle planning system. All patients were treated with a 6-MV or 8-MV linear accelerator.~Chemotherapy: All patients received two cycles of chemotherapy concurrently with radiotherapy. Patients assigned to the DP group received two cycles of DP regimen (docetaxel 60 mg/m2 delivered on day 1 and cisplatin 80 mg/m2 delivered on day 1) at a 3-week interval. In cases of grade 4 hematologic toxicity or severe non-hematologic toxicities, dose adjustment was performed in the subsequent chemotherapy cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Radiotherapy: All patients underwent conventional radiotherapy, 1.8-2.0 Gy per fraction and 5 fractions per week. The prescribed dose was 60-64 Gy to PTV1 and 50 Gy to PTV2. Patients received either three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiation therapy (IMRT). 3D-CRT treatment plans were calculated by Pinnacle planning system and IMRT treatment plans were calculated by Monacle planning system. All patients were treated with a 6-MV or 8-MV linear accelerator.~Chemotherapy: All patients received two cycles of chemotherapy concurrently with radiotherapy. Patients assigned to the PF group received two cycles of PF regimen (cisplatin 80 mg/m2 delivered on day 1 and 5-FU 1000 mg/m2 continuous infusion over 24 hours daily on days 1-4) at a 3-week interval. In cases of grade 4 hematologic toxicity or severe non-hematologic toxicities, dose adjustment was performed in the subsequent chemotherapy cycle.
Study: NCT02094573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Brigatinib tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Brigatinib tablets
Study: NCT01169389

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraarticular injection
Description: Durolane, one vial

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intra-articular injection of 0.5% Bupivacaine
Study: NCT01650389

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA85A

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Candin

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG Vaccine SSI
Description: All infants who test negative by HIV PCR will receive BCG vaccination at 8 weeks of age.~Infants who test positive by HIV PCR will not receive BCG vaccination.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG Vaccine SSI
Description: All infants who test negative by HIV PCR will receive BCG vaccination at 8 weeks of age.~Infants who test positive by HIV PCR will not receive BCG vaccination.
Study: NCT00607906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-756050 immediate release capsule
Description: SB-756050 immediate release capsules will be size 0, white, opaque capsules with no identifying markings, containing white to off-white drug layered pellets. Each capsule will contain 5, 25 or 100 milligrams of SB-756050.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-756050 immediate release capsule
Description: SB-756050 immediate release capsules will be size 0, white, opaque capsules with no identifying markings, containing white to off-white drug layered pellets. Each capsule will contain 5, 25 or 100 milligrams of SB-756050.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-756050 immediate release capsule
Description: SB-756050 immediate release capsules will be size 0, white, opaque capsules with no identifying markings, containing white to off-white drug layered pellets. Each capsule will contain 5, 25 or 100 milligrams of SB-756050.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-756050 immediate release capsule
Description: SB-756050 immediate release capsules will be size 0, white, opaque capsules with no identifying markings, containing white to off-white drug layered pellets. Each capsule will contain 5, 25 or 100 milligrams of SB-756050.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-756050 immediate release capsule
Description: SB-756050 immediate release capsules will be size 0, white, opaque capsules with no identifying markings, containing white to off-white drug layered pellets. Each capsule will contain 5, 25 or 100 milligrams of SB-756050.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-756050 modified release capsule
Description: SB-756050 modified release capsules will be size 0, white, opaque capsules with no identifying markings, containing white to off-white enteric coated drug layered pellets. Each capsule will contain either 25or 100 milligrams of SB-756050.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-756050 modified release capsule
Description: SB-756050 modified release capsules will be size 0, white, opaque capsules with no identifying markings, containing white to off-white enteric coated drug layered pellets. Each capsule will contain either 25or 100 milligrams of SB-756050.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will also receive placebo capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will also receive placebo capsules.
Study: NCT03975673

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hip replacement
Description: Osteoarthritic patient undergoing the conventional technique or the kinematically aligned technique
Study: NCT01284400

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based disease management
Description: Symptom monitoring, comprehensive advice, and counseling at home by nurses, as well as telephone follow-up by nurses
Study: NCT01136824

Intervention type: OTHER
Intervention: Questionnaires
Description: Subjects will be given a series of questionnaires to assess the effect of AI chemotherapy, and the possible role of tumor load, on the amount of symptoms. The extent of nausea, vomiting, fatigue, anxiety, sleep disturbance, and cognitive changes will be measured. In adjuvant chemotherapy patients, we will also assess the relationship between tumor size and amount of chemotherapy-induced symptoms. These questionnaires will involve the following assessments:~Demographic \& health Trait anxiety Quality of life Nausea Expectations Anxiety \& total mood disturbance Nausea \& vomiting Multiple symptoms
Study: NCT04901559

Intervention type: PROCEDURE
Intervention: Graft type at ACLR
Description: The choice of graft at primary ACL Reconstruction

Intervention type: PROCEDURE
Intervention: Graft type at ACLR
Description: The choice of graft at primary ACL Reconstruction

Intervention type: PROCEDURE
Intervention: Graft type at ACLR
Description: The choice of graft at primary ACL Reconstruction
Study: NCT01700946

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: given intravenously or orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: given intravenously or orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate
Description: given intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate
Description: given intravenously
Study: NCT00607906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will also receive placebo capsules.
Study: NCT01700946

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: given intravenously

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: given intravenously
Study: NCT00607906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will also receive placebo capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will also receive placebo capsules.
Study: NCT01700946

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clofarabine
Description: given intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clofarabine
Description: given intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: given intravenously
Study: NCT00545441

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgisis Biodesign Anal Fistula Plug (Surgisis® AFP)
Description: Surgical placement of the Surgisis AFP is performed under general anesthesia.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flap
Description: Advancement flap surgery is performed; no anal fistula plug is placed
Study: NCT01168934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib
Description: Treatment A: Intravenous dose of 50 mg crizotinib will be administered as directed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib
Description: Treatment B: Oral dose of 250 mg crizotinib as 1 × 50-mg Immediate Release Tablet and 2 × 100-mg Immediate Release Tablets will be administered in the fasted state as directed.
Study: NCT02211989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 14332 CL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04163276

Intervention type: DIAGNOSTIC_TEST
Intervention: 18F FDG PET exam
Description: All patients have received 18F-FDG PET/CT in nuclear medicine

Intervention type: DIAGNOSTIC_TEST
Intervention: 18F FDG PET exam
Description: All patients have received 18F-FDG PET/CT in nuclear medicine
Study: NCT02540239

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 2L PEG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2L PEG+simethicone
Study: NCT03750916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride plus Docetaxel
Description: Anlotinib Hydrochloride (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
Study: NCT03753126

Intervention type: RADIATION
Group type: OTHER
Intervention: 4-dimensional volume-rendered computed tomography
Study: NCT01351129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 1
Description: 150-mg immediate release tablet (single dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 2
Description: 150-mg modified release capsule, short duration (single dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 3
Description: 150-mg modified release capsule, long duration (single dose)
Study: NCT02677805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A
Description: Injection, 20 Units divided in five 0.1mL i.m injections into the glabellar area

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: injection, sodium chloride 0.9% divided in five 0.1 mL i.m. injections into the glabellar area

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A - Open Label
Description: Open Label Extension Phase with Experimental Drug; Injection, 20 Units divided in five 0.1mL i.m injections into the glabellar area
Study: NCT05002101

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: zinc
Description: The zinc syrup was prepared with a concentration of 7 mg zinc in each 5 ml solution. Accordingly, children with weight more than 10 kg were asked to take 5 ml syrup daily, while children with weight less than 10 kg were asked to take 2.5 ml daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Children with weight more than 10 kg were asked to take 5 ml syrup daily, while children with weight less than 10 kg were asked to take 2.5 ml daily.
Study: NCT00973531

Intervention type: DEVICE
Group type: OTHER
Intervention: Autotitrating Positive Airway Pressure (APAP)
Description: Then subjects will use Autotitrating Positive Airway Pressure machine for 90 days

Intervention type: DEVICE
Group type: OTHER
Intervention: Traditional Split Titration Polysomnogram
Description: Then subjects will use Continuous Positive Airway Pressure (CPAP) machine for 90 days
Study: NCT03285412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib is a drug designed to block certain proteins called cyclin-dependent protein kinases 4 and 6 (CDK4/6). These proteins are needed for cells to divide and may also control the ability of certain cancers to grow.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endocrine therapy
Description: Hormone therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Description: Hormone therapy
Study: NCT03932838

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical and radiologic evaluation
Description: Follow up post surgery: clinical and radiologic evaluation
Study: NCT00828581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lorcaserin
Study: NCT00756652

Intervention type: DEVICE
Intervention: Mentor Silicone Gel-Filled Breast Implants

Intervention type: DEVICE
Intervention: Saline Breast Implants
Study: NCT02564952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P
Description: GWP42003-P was presented as an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants received up to a maximum of 30 mg/kg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobazam
Description: Participants were taking CLB upon entry into the OLE phase of the trial. CLB was not an investigational medicinal product (IMP) for the OLE phase and was not administered by the Sponsor, but was administered at the physician's discretion, as required for each participant. CLB could be stopped, if clinically indicated, without impact on analysis.
Study: NCT03308123

Intervention type: OTHER
Intervention: Observational study, not interventional
Description: Not an intervention study

Intervention type: OTHER
Intervention: Observational study, not interventional
Description: Not an intervention study

Intervention type: OTHER
Intervention: Observational study, not interventional
Description: Not an intervention study
Study: NCT02341209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline monohydrate
Description: Doxycycline will be administered in either tablets or capsules for either five months or a year depending on response.
Study: NCT03262519

Intervention type: DIAGNOSTIC_TEST
Intervention: Computer based neurocognitive testing
Description: Iowa Gambling Task, The Balloon Task, Intertemporal choices task, Cognitive Reflection Test, Physiological and self-reported measures of OSA/sleep related symptoms, General health and physiological measures.
Study: NCT02977494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab (JNJ-54767414) is a novel human IgG1monoclonal Antibody (mAb) that binds with high affinity to a unique epitope on CD38

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT01288417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: boceprevir
Description: 10 days of boceprevir 800mg TID
Study: NCT04884126

Intervention type: PROCEDURE
Intervention: dental implant placement
Description: The time of dental implant surgery

Intervention type: PROCEDURE
Intervention: dental implant placement
Description: The time of dental implant surgery
Study: NCT01288417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir
Description: raltegravir 400mg single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: raltegravir
Description: raltegravir 400mg single dose
Study: NCT01125358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: Administered orally, twice daily for up to 7 weeks of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: Administered orally, twice daily for up to 7 weeks of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: Administered orally, twice daily for up to 7 weeks of treatment
Study: NCT04304690

Intervention type: OTHER
Group type: OTHER
Intervention: blood sample
Description: 2 blood samples at T0 and 3 months
Study: NCT02048956

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrotherapy intervention
Description: Participants randomized to the exercise programme received a training in a swimming pool focused on dance therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Standard exercises of hydrotherapy
Study: NCT00592449

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) for insomnia
Description: During CBT, participants will learn how to change their sleeping habits and reduce arousal and alertness while trying to sleep. Participants will attend 8 weekly CBT sessions with a psychologist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral desensitization treatment for insomnia
Description: The behavioral desensitization treatment is designed to decondition states of arousal that interfere with sleep. Participants will attend 8 weekly behavioral desensitization treatment sessions with a psychologist.
Study: NCT03335657

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBPT
Description: The CBPT program focuses on a patient-oriented cognitive-behavioral self-management approach to improve physical function and reduce pain, through reductions in pain catastrophizing and fear of movement and increases in self-efficacy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Education Treatment
Description: Participants receiving the education control arm are receiving a placebo intervention to control for the attention of the interventionist. They will receive standardized educational material addressing recovery from orthopaedic trauma.
Study: NCT00907270

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Cholecalciferol: 4,000 IU/day and 400 IU/day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Cholecalciferol: 4,000 IU/day and 400 IU/day
Study: NCT02323464

Intervention type: PROCEDURE
Intervention: Surgery for colorectal cancer
Description: Includes open and minimally invasive surgery for colon- and rectal cancer

Intervention type: OTHER
Intervention: No Interventions
Description: This is a control group from the population. They are not scheduled for surgery
Study: NCT02091518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MR Screening Questionnaire
Description: All participants will complete the MR Screening Questionnaire before the MRI exam. During the MRI exam, all participants will be observed through the window from the operator console. Verbal communication will be kept with the participant throughout the exam via a speaker system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging Acquisition and Analysis
Description: MRI Studies: The MRI scans will be performed on a 1.5T or 3T MRI scanner. Conventional MRI studies will be performed using the standard clinical sequences. The new research sequences will be performed.at any point during the clinical exam. Total imaging time for volunteers will be 30-45 minutes.